HRAS antibody (AA 104-128)

Catalog No. ABIN3029525

Product Details anti-HRAS Antibody

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Binding Specificity: AA 104-128

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HRAS antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Cross-Reactivity (Details): Expected species reactivity: Mouse, Rat

Purification: Purified

Immunogen: A portion of amino acids 104-128 from the human protein was used as the immunogen for this HRAS antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the HRAS antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:500-1000,IHC (Paraffin): 1:10-1:50,Immunofluorescence: 1:10-1:50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the HRAS antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for HRAS

Target: HRAS (HRas proto-oncogene, GTPase (HRAS))

Alternative Name: HRAS (HRAS Products)

Background: HRAS belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. These proteins function in signal transduction pathways. They can bind GTP and GDP, and they have intrinsic GTPase activity. HRAS undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in the HRAS gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma.

UniProt: P01112

Pathways: p53 Signaling, MAPK Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Hepatitis C, Autophagy, Signaling Events mediated by VEGFR1 and VEGFR2, Signaling of Hepatocyte Growth Factor Receptor, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling, BCR Signaling